Profile - To The Moon

Meeeyeee

Posts · 4Posts · 4
Following · 0Following · 0
Followers · 0Followers · 0

- MeeeyeeeMeeeyeee
  ·2021-06-24
  Wow
  Sorry, this post has been deleted
  2.32K 1
  Like
  Share
  Report
- MeeeyeeeMeeeyeee
  ·2021-06-24
  Good
  Chaoju Ophthalmology will launch its IPO today, and the first-hand admission fee is about HK $5353.41
  6月24日，朝聚眼科发布公告，公司于6月24日至6月29日招股；公司拟全球发售1.7093亿股股份，其中香港发售股份1709.3万股，国际发售股份1.53837亿股；每股发行价9.48-10.60港元
  Chaoju Ophthalmology will launch its IPO today, and the first-hand admission fee is about HK $5353.41
  1.46K Comment
  Like
  Share
  Report

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3586321020229596","uuid":"3586321020229596","gmtCreate":1623226995679,"gmtModify":1624633551176,"name":"Meeeyeee","pinyin":"meeeyeee","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/d84d3fa5e9065af6576554da271d7398","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":2,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.07.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":128119979,"gmtCreate":1624505432591,"gmtModify":1703838668780,"author":{"id":"3586321020229596","authorId":"3586321020229596","name":"Meeeyeee","avatar":"https://static.tigerbbs.com/d84d3fa5e9065af6576554da271d7398","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586321020229596","idStr":"3586321020229596"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/128119979","repostId":"1130976510","repostType":4,"isVote":1,"tweetType":1,"viewCount":2320,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128132262,"gmtCreate":1624505182156,"gmtModify":1703838662802,"author":{"id":"3586321020229596","authorId":"3586321020229596","name":"Meeeyeee","avatar":"https://static.tigerbbs.com/d84d3fa5e9065af6576554da271d7398","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586321020229596","idStr":"3586321020229596"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/128132262","repostId":"1136951406","repostType":4,"repost":{"id":"1136951406","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624497362,"share":"https://ttm.financial/m/news/1136951406?lang=en_US&edition=fundamental","pubTime":"2021-06-24 09:16","market":"hk","language":"zh","title":"Chaoju Ophthalmology will launch its IPO today, and the first-hand admission fee is about HK $5353.41","url":"https://stock-news.laohu8.com/highlight/detail?id=1136951406","media":"老虎资讯综合","summary":"6月24日，朝聚眼科发布公告，公司于6月24日至6月29日招股；公司拟全球发售1.7093亿股股份，其中香港发售股份1709.3万股，国际发售股份1.53837亿股；每股发行价9.48-10.60港元","content":"<p>On June 24, Chaoju Ophthalmology issued an announcement that the company will issue an IPO from June 24 to June 29; The company plans to sell 170.93 million shares globally, including 17.093 million shares offered in Hong Kong and 153.837 million shares offered internationally; The issue price per share is 9.48-10.60 Hong Kong dollars, each lot is 500 shares, and the admission fee is about 5353.41 Hong Kong dollars; Haitong International and Huatai International are joint sponsors, and it is expected that the shares will be listed on the main board of the Stock Exchange on July 7.</p><p><b>Tiger Trade will open for subscription at 11:30 [</b><a href=\"https://www-web.itiger.com/mi/ipo/index/hk/listing\" target=\"_blank\"><b>Subscription entrance</b></a><b>】</b></p><p><img src=\"https://static.tigerbbs.com/396a841474a75b2709096e6774872273\" tg-width=\"850\" tg-height=\"763\" referrerpolicy=\"no-referrer\"></p><p><b>Subscription ladder:</b></p><p>There are 500 shares per lot, and the admission fee is HK $5,353.41.</p><p>The threshold for Group B is 500,000 shares, and the funds required for subscription are approximately HK $5,353,408.1.</p><p><img src=\"https://static.tigerbbs.com/3ad211e1911379810ca70b4c49d2cfe8\" tg-width=\"1153\" tg-height=\"662\" referrerpolicy=\"no-referrer\"></p><p>The Group is a leading and nationally renowned ophthalmic medical service group in North China. According to the Frost & Sullivan Report, among private eye hospitals, the Group ranked first in Inner Mongolia, second in North China and fifth in China in terms of total revenue in 2020. China has a large and rapidly growing ophthalmic medical service market. According to the Frost & Sullivan Report, the size of China's ophthalmic medical service market increased from RMB 73 billion in 2015 to RMB 127.5 billion in 2019, with a compound annual growth rate of 15.0%, and is expected to further increase to RMB 223.1 billion in 2024; The size of the ophthalmic medical service market in North China increased from RMB 13.2 billion in 2015 to RMB 21.2 billion in 2019, with a compound annual growth rate of 12.5%, and is expected to further grow to RMB 33.7 billion in 2024; The size of the ophthalmic medical service market in Inner Mongolia increased from RMB1.1 billion in 2015 to RMB2 billion in 2019, representing a CAGR of 15.6%, and is expected to further grow to RMB3.3 billion in 2024. With the increasing population and the strong demand for ophthalmic medical services, the growth potential of the ophthalmic medical services market in China is expected to be huge. Leveraging on the Group's experience and market leadership in ophthalmic services, the Group believes that the Group is well positioned to seize the growing opportunities and benefit from the rapid expansion of China's ophthalmic services market.</p><p>During the Track Record Period, the Group experienced rapid growth. The Group's revenue increased by 13.0% from RMB 632.7 million in 2018 to RMB 714.7 million in 2019, and further increased by 11.1% to RMB 794.3 million in 2020. The group's net profit also increased significantly from RMB 29.2 million in 2018 to RMB 70.8 million in 2019, and further increased by 70.2% to RMB 120.5 million in 2020. In 2018, 2019 and 2020, the number of patient visits to the Group's hospitals was 638,650, 702,143 and 696,206, respectively, and the number of client visits to the optometry center was 73,935, 79,903 and 91,660, respectively.</p><p><img src=\"https://static.tigerbbs.com/9b85516f9bf7cbda5d3618c2a26e58d7\" tg-width=\"957\" tg-height=\"639\" referrerpolicy=\"no-referrer\"></p><p>The Group has entered into a Cornerstone Investment Agreement with the Cornerstone Investor, pursuant to which the Cornerstone Investor has agreed to subscribe for, or procure its designated entity to subscribe for, a certain number of Offer Shares at the Offer Price. The cornerstone investors have agreed to subscribe for the relevant number of Offer Shares available at the Offer Price, totaling US $102 million or approximately HK $792 million. Calculated based on the offer price of HK $10.04 per share (i.e. the mid-point of the offer price range), assuming that the over-allotment option is not exercised, the total number of shares to be subscribed by cornerstone investors is 78.8395 million shares, accounting for approximately 46.12% of the offer shares and immediately following the completion of the global offering The total issued share capital is approximately 11.47%. Cornerstone investors include Wells Fargo Fund Management Limited, Gigantic Wealth Holdings Limited, Tongbai Capital (Hong Kong) Limited, and The Valliance Fund.</p><p><img src=\"https://static.tigerbbs.com/bec0f4980a5f1eb938ada0e1abe84825\" tg-width=\"946\" tg-height=\"629\" referrerpolicy=\"no-referrer\"></p><p>Assuming an offer price of HK $10.04 per share (the mid-point of the offer price range), and assuming that the over-allotment option is not exercised, the Group estimates that the net proceeds received from the global offering will be approximately HK $1,283.2 million. Among them, approximately 35.8% of the net proceeds from the global offering will be used to establish new hospitals and relocate, upgrade and decorate existing hospitals; Approximately 44.8% will be used to acquire hospitals in new markets with large populations and relatively high demand for ophthalmic medical services when suitable opportunities arise; About 9.4% will be used to upgrade the Group's information technology system; And approximately 10.0% will be used for working capital and other general corporate purposes.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chaoju Ophthalmology will launch its IPO today, and the first-hand admission fee is about HK $5353.41</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChaoju Ophthalmology will launch its IPO today, and the first-hand admission fee is about HK $5353.41\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-06-24 09:16</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On June 24, Chaoju Ophthalmology issued an announcement that the company will issue an IPO from June 24 to June 29; The company plans to sell 170.93 million shares globally, including 17.093 million shares offered in Hong Kong and 153.837 million shares offered internationally; The issue price per share is 9.48-10.60 Hong Kong dollars, each lot is 500 shares, and the admission fee is about 5353.41 Hong Kong dollars; Haitong International and Huatai International are joint sponsors, and it is expected that the shares will be listed on the main board of the Stock Exchange on July 7.</p><p><b>Tiger Trade will open for subscription at 11:30 [</b><a href=\"https://www-web.itiger.com/mi/ipo/index/hk/listing\" target=\"_blank\"><b>Subscription entrance</b></a><b>】</b></p><p><img src=\"https://static.tigerbbs.com/396a841474a75b2709096e6774872273\" tg-width=\"850\" tg-height=\"763\" referrerpolicy=\"no-referrer\"></p><p><b>Subscription ladder:</b></p><p>There are 500 shares per lot, and the admission fee is HK $5,353.41.</p><p>The threshold for Group B is 500,000 shares, and the funds required for subscription are approximately HK $5,353,408.1.</p><p><img src=\"https://static.tigerbbs.com/3ad211e1911379810ca70b4c49d2cfe8\" tg-width=\"1153\" tg-height=\"662\" referrerpolicy=\"no-referrer\"></p><p>The Group is a leading and nationally renowned ophthalmic medical service group in North China. According to the Frost & Sullivan Report, among private eye hospitals, the Group ranked first in Inner Mongolia, second in North China and fifth in China in terms of total revenue in 2020. China has a large and rapidly growing ophthalmic medical service market. According to the Frost & Sullivan Report, the size of China's ophthalmic medical service market increased from RMB 73 billion in 2015 to RMB 127.5 billion in 2019, with a compound annual growth rate of 15.0%, and is expected to further increase to RMB 223.1 billion in 2024; The size of the ophthalmic medical service market in North China increased from RMB 13.2 billion in 2015 to RMB 21.2 billion in 2019, with a compound annual growth rate of 12.5%, and is expected to further grow to RMB 33.7 billion in 2024; The size of the ophthalmic medical service market in Inner Mongolia increased from RMB1.1 billion in 2015 to RMB2 billion in 2019, representing a CAGR of 15.6%, and is expected to further grow to RMB3.3 billion in 2024. With the increasing population and the strong demand for ophthalmic medical services, the growth potential of the ophthalmic medical services market in China is expected to be huge. Leveraging on the Group's experience and market leadership in ophthalmic services, the Group believes that the Group is well positioned to seize the growing opportunities and benefit from the rapid expansion of China's ophthalmic services market.</p><p>During the Track Record Period, the Group experienced rapid growth. The Group's revenue increased by 13.0% from RMB 632.7 million in 2018 to RMB 714.7 million in 2019, and further increased by 11.1% to RMB 794.3 million in 2020. The group's net profit also increased significantly from RMB 29.2 million in 2018 to RMB 70.8 million in 2019, and further increased by 70.2% to RMB 120.5 million in 2020. In 2018, 2019 and 2020, the number of patient visits to the Group's hospitals was 638,650, 702,143 and 696,206, respectively, and the number of client visits to the optometry center was 73,935, 79,903 and 91,660, respectively.</p><p><img src=\"https://static.tigerbbs.com/9b85516f9bf7cbda5d3618c2a26e58d7\" tg-width=\"957\" tg-height=\"639\" referrerpolicy=\"no-referrer\"></p><p>The Group has entered into a Cornerstone Investment Agreement with the Cornerstone Investor, pursuant to which the Cornerstone Investor has agreed to subscribe for, or procure its designated entity to subscribe for, a certain number of Offer Shares at the Offer Price. The cornerstone investors have agreed to subscribe for the relevant number of Offer Shares available at the Offer Price, totaling US $102 million or approximately HK $792 million. Calculated based on the offer price of HK $10.04 per share (i.e. the mid-point of the offer price range), assuming that the over-allotment option is not exercised, the total number of shares to be subscribed by cornerstone investors is 78.8395 million shares, accounting for approximately 46.12% of the offer shares and immediately following the completion of the global offering The total issued share capital is approximately 11.47%. Cornerstone investors include Wells Fargo Fund Management Limited, Gigantic Wealth Holdings Limited, Tongbai Capital (Hong Kong) Limited, and The Valliance Fund.</p><p><img src=\"https://static.tigerbbs.com/bec0f4980a5f1eb938ada0e1abe84825\" tg-width=\"946\" tg-height=\"629\" referrerpolicy=\"no-referrer\"></p><p>Assuming an offer price of HK $10.04 per share (the mid-point of the offer price range), and assuming that the over-allotment option is not exercised, the Group estimates that the net proceeds received from the global offering will be approximately HK $1,283.2 million. Among them, approximately 35.8% of the net proceeds from the global offering will be used to establish new hospitals and relocate, upgrade and decorate existing hospitals; Approximately 44.8% will be used to acquire hospitals in new markets with large populations and relatively high demand for ophthalmic medical services when suitable opportunities arise; About 9.4% will be used to upgrade the Group's information technology system; And approximately 10.0% will be used for working capital and other general corporate purposes.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","relate_stocks":{"02219":"朝聚眼科"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136951406","content_text":"6月24日，朝聚眼科发布公告，公司于6月24日至6月29日招股；公司拟全球发售1.7093亿股股份，其中香港发售股份1709.3万股，国际发售股份1.53837亿股；每股发行价9.48-10.60港元，每手买卖单位500股，入场费约5353.41港元；海通国际及华泰国际为联席保荐人，预期股份将于7月7日于联交所主板挂牌上市。\nTiger Trade将于11:30开放申购【申购入口】\n\n申购阶梯：\n每手500股，入场费5353.41港元。\n乙组门槛为50万股，申购所需资金约5353408.1港元。\n\n集团是中国华北地区领先、全国知名的眼科医疗服务集团。根据弗若斯特沙利文报告，于民营眼科医院中，按2020年的收益总额计，集团在内蒙古排名第一、在中国华北地区排名第二及在中国排名第五。中国拥有一个庞大且快速成长的眼科医疗服务市场。根据弗若斯特沙利文报告，中国眼科医疗服务市场的规模从2015年的人民币730亿元增加至2019年的人民币1,275亿元，复合年增长率达15.0%，预计将进一步增至2024年的人民币2,231亿元；中国华北地区眼科医疗服务市场的规模从2015年的人民币132亿元增加至2019年的人民币212亿元，复合年增长率达12.5%，预计将进一步增长至2024年的人民币337亿元；内蒙古眼科医疗服务市场的规模由2015年的人民币11亿元增至2019年的人民币20亿元，复合年增长率达15.6%，预期将进一步增长至2024年的人民币33亿元。随着人口增加，加上眼科医疗服务需求殷切，预期中国眼科医疗服务市场的增长潜力庞大。凭藉集团于眼科服务的经验及市场领先优势，集团相信集团处于有利位置以把握不断增长的机遇，并从中国眼科服务市场的快速扩展中受惠。\n于往绩记录期间，集团迎来快速增长。集团的收益由2018年的人民币6.327亿元增加13.0%至2019年的人民币7.147亿元，并进一步增加11.1%至2020年的人民币7.943亿元。集团的纯利亦由2018年的人民币2920万元大幅增加至2019年的人民币7080万元，并进一步增加70.2%至2020年的人民币1.205亿元。于2018年、2019年及2020年，集团医院的患者就诊人次分别为638,650名、702,143名及696,206名，且视光中心的客户就诊人次分别为73,935名、79,903名及91,660名。\n\n集团已与基石投资者订立基石投资协议，据此，基石投资者已同意按发售价认购或促使其指定实体按发售价认购若干数目的发售股份。基石投资者已同意按发售价认购可认购有关数目的发售股份，总额为1.02亿美元或约7.92亿港元。按发售价每股10.04港元(即发售价范围中位数)计算，假设超额配股权不获行使，基石投资者将予认购的股份总数为7883.95万股，占发售股份约46.12%及紧随全球发售完成后已发行股本总额约11.47%。基石投资者包括富国基金管理有限公司、Gigantic Wealth Holdings Limited、通柏资本(香港)有限公司、及The Valliance Fund。\n\n假设发售价为每股10.04港元(即发售价范围中位数)，并假设超额配股权未获行使，集团估计收取的全球发售所得款项净额将约为12.832亿港元。其中，全球发售所得款项净额约35.8%将用于建立新医院以及搬迁、升级及装修现有医院；约44.8%将在出现合适机遇时，用于在人口庞大且对眼科医疗服务需求相对较高的新市场中收购医院；约9.4%将用于升级集团的信息技术系统；及约10.0%将用于营运资金及其他一般企业用途。","news_type":1,"symbols_score_info":{"02219":0.9}},"isVote":1,"tweetType":1,"viewCount":1463,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}